Glaukos Corporation (GKOS) News
Filter GKOS News Items
GKOS News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
GKOS News Highlights
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
Latest GKOS News From Around the Web
Below are the latest news stories about GLAUKOS CORP that investors may wish to consider to help them evaluate GKOS as an investment opportunity.
Here's Why You Should Add Glaukos Stock to Your Portfolio NowGKOS continues to benefit from robust product demand and expansion in new markets. A strong development pipeline raises optimism. |
Glaukos Reaches 52-Week High: What's Driving the Stock's Rally?Investors are optimistic about GKOS' strength in its product portfolio amid robust demand and expansion in new markets. |
Glaukos price target raised to $157 from $149 at BTIGBTIG raised the firm’s price target on Glaukos (GKOS) to $157 from $149 and keeps a Buy rating on the shares as part of a broader research note updating the firm’s models on Medical Technology names reflecting management commentary, product launch momentum, competitive updates, and macroeconomic factors. For Glaukos, with the iDose launch moving into 2025 in a more “coordinated and established manner”, the firm is incorporating its iDose sales estimates into specific revenue estimates going forw |
Glaukos Stock Down Despite NDA Submission of Epioxa to the FDAGKOS announces New Drug Application submission for its Epioxa to the FDA. |
Glaukos Submits New Drug Application to U.S. FDA for Epioxa™ALISO VIEJO, Calif., December 23, 2024--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced the submission of its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for Epioxa™ (Epi-on), its next-generation corneal cross-linking iLink therapy for the treatment of keratoconus, a progressive, sight-threatening corneal dis |
The three-year returns have been stellar for Glaukos (NYSE:GKOS) shareholders despite underlying losses increasingThe worst result, after buying shares in a company (assuming no leverage), would be if you lose all the money you put... |
Glaukos price target raised to $185 from $152 at TruistTruist analyst Richard Newitter raised the firm’s price target on Glaukos (GKOS) to $185 from $152 and keeps a Buy rating on the shares as part of a broader research note previewing 2025 in Medical Technology. The firm sees the sector as “one of the better/safer houses” in healthcare given its lower “front-line” exposure to healthcare policy rhetoric that is tied to the administration change as well as its position as an “innovation segment” with sustainable above-average revenue and EPS growth, |
Glaukos Announces Participation in the J.P. Morgan Healthcare ConferenceALISO VIEJO, Calif., December 17, 2024--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that its management is scheduled to participate in the 43rd Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, 2025, at 5:15 p.m. PT in San Francisco, CA. |
The Zacks Analyst Blog Intuitive Surgical, Globus Medical, Glaukos, Veracyte and InogenIntuitive Surgical, Globus Medical, Glaukos, Veracyte and Inogen are included in this Analyst Blog. |
5 Medical Device Stocks That Survived the 2024 Market VolatilityHere, we discuss five medical device stocks, namely ISRG, GMED, GKOS, VCYT and INGN, which gained in 2024 despite ongoing challenges and provide an attractive investment opportunity for 2025. |